Groundbreaking Partnership for Personalized Gene Therapy to Help Young Kosta with ARCA2 Disorder

A New Hope for Kosta: Advancing Gene Therapy for ARCA2 Disorder

In a significant stride towards personalized medicine, Genezen, a leading gene therapy contract development and manufacturing organization (CDMO), has recently announced its collaboration with Nevena Lešević, a determined mother from Lazarevac, Serbia, and the University of Missouri. This groundbreaking partnership aims to develop a tailored AAV9 gene therapy specifically for Nevena's son, Kosta, who is afflicted with the ultra-rare condition known as autosomal recessive spinocerebellar ataxia-2 (ARCA2).

The Journey Begins

Kosta was diagnosed with ARCA2 at the tender age of two, following a COVID-19 infection that resulted in substantial developmental regression. This rare disorder stems from a mutation in the PMPCA gene, which severely impacts motor functions, leading to symptoms such as unsteady walking, balance issues, epilepsy, tremors, and speech difficulties. It is reported that this specific mutation affects only about 25 individuals globally, indicating the urgent need for novel therapeutic approaches.

Nevena, driven by her maternal instincts, embarked on a relentless quest to find answers and potential cures for her son. In 2023, both Kosta's parents underwent comprehensive genetic testing that revealed they are carriers of two distinct mutations. Later that year, Kosta participated in various clinical studies, which initially suggested some improvement in his condition, but he has since been experiencing setbacks.

Collaboration with Experts

Recognizing the gravity of Kosta's situation, Nevena sought assistance from Professor Smita Saxena, PhD, and her research team at the University of Missouri's NextGen Precision Health initiative. Their mission focuses on understanding the mechanisms behind neurodegenerative diseases, particularly those affecting the cerebellum, like ARCA2. Together, they are working on a unique AAV9 gene therapy for Kosta’s case, envisioned as an N-of-1 clinical trial.

A Unique Trial Type

N-of-1 gene therapies represent a crucial avenue in providing personalized treatments in scenarios where conventional standard care is inadequate or nonexistent. However, such therapies often face barriers due to traditional manufacturing processes that emphasize scalability and a one-size-fits-all approach. Genezen aims to bridge this gap by leveraging its experience in viral vector manufacturing while tailoring its operations to expedite the production of Kosta’s personalized therapy.

Community Support and Family Resilience

Beyond the scientific efforts, Nevena and Kosta's story exemplifies the power of community support. They frequently travel to Barcelona, Spain, where Kosta receives specialized medical treatment and ongoing evaluations. Nevena is surrounded by a network of family and friends, notably her sisters and parents, whose unwavering encouragement fuels her resolve to seek out innovative treatment avenues for her son.

Nevena shares her journey, stating, "As a parent of a child with an ultra-rare disease, you quickly become an expert in ways and subjects you never imagined. Over the last few years, I have taught myself to be a geneticist, scientist, and a drug developer—all in the name of helping Kosta become himself once again."

Commitment from Genezen

According to Steve Favaloro, Chairman and CEO of Genezen, the company's involvement in this project underscores its mission to empower parent-led initiatives aimed at addressing rare diseases. He emphasizes, "Nevena and Kosta's experience highlights resilience, and we are committed to producing a viable therapy for Kosta through our manufacturing capabilities."

A Collaborative Future

As the partnership progresses, the hope is that this innovative approach to personalized AAV9 gene therapy will not only restore Kosta's capabilities but also inspire future endeavors in the realm of precision medicine. Professor Saxena remarks, "By combining Nevena's commitment with our scientific expertise and collaborating with a proficient manufacturer like Genezen, we are on the path to creating a trial that could provide Kosta with a new lease on life."

In conclusion, this partnership is more than just a medical endeavor; it is a testament to a mother's love, resilience, and the power of collaboration in the fight against rare diseases. As researchers and families align to confront challenges together, the future holds hope not only for Kosta but also for many others battling similar conditions.